US Bancorp
FDMT icon

US Bancorp’s 4D Molecular Therapeutics FDMT Stock Holding History

US Bancorp’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$326 Buy
+35
New +$305 ﹤0.01% 4046
2025
Q4 		– Sell
-57
Closed -$495 – 4095
2025
Q3 		$495 Buy
+57
New +$341 ﹤0.01% 3873
2025
Q1 		– Sell
-247
Closed -$1.38K – 4259
2024
Q4 		$1.38K Sell
247
-755
-75% -$5.92K ﹤0.01% 3917
2024
Q3 		$10.8K Sell
1,002
-102
-9% -$1.69K ﹤0.01% 3348
2024
Q2 		$23.2K Sell
1,104
-756
-41% -$19K ﹤0.01% 3009
2024
Q1 		$59.3K Buy
1,860
+63
+4% +$1.61K ﹤0.01% 2599
2023
Q4 		$36.4K Buy
1,797
+1,533
+581% +$20.2K ﹤0.01% 2825
2023
Q3 		$3.36K Hold
264
– – ﹤0.01% 3545
2023
Q2 		$4.77K Buy
+264
New +$4.86K ﹤0.01% 3490
2023
Q1 		– Sell
-113
Closed -$2.51K – 4123
2022
Q4 		$2.51K Sell
113
-259
-70% -$4K ﹤0.01% 3718
2022
Q3 		$3K Sell
372
-352
-49% -$3.19K ﹤0.01% 3729
2022
Q2 		$5K Sell
724
-680
-48% -$6.61K ﹤0.01% 3580
2022
Q1 		$21K Buy
1,404
+695
+98% +$10.9K ﹤0.01% 3043
2021
Q4 		$16K Buy
709
+391
+123% +$9.58K ﹤0.01% 3230
2021
Q3 		$9K Buy
318
+298
+1,490% +$8.5K ﹤0.01% 3473
2021
Q2 		$0 Buy
+20
New +$612 ﹤0.01% 4018

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

US Bancorp's FDMT Position: Q1 2026 in Review

US Bancorp opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 35 shares worth $326. The stake represents ﹤0.01% of the portfolio and ranks #4046 among its holdings. This is a return to the name: US Bancorp previously reported a position in FDMT as recently as Q3 2025.

US Bancorp first reported a position in FDMT in Q2 2021 and has held it in 16 quarters since. The position peaked at $59.3K in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • US Bancorp held 35 shares of 4D Molecular Therapeutics worth $326 as of Q1 2026.
  • 4D Molecular Therapeutics was a new US Bancorp position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4046 holding.
  • US Bancorp first reported a position in 4D Molecular Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • US Bancorp's 4D Molecular Therapeutics position peaked at $59.3K in Q1 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.